Germany's Medios cuts 2026 EBITDA outlook on pharma supply price pressure

Medios AG

28/07/2026 18:57

Overview
Germany specialty pharma firm's preliminary H1 2026 revenue rose yr/yr, topping €1 bln
Preliminary H1 2026 adjusted EBITDA declined slightly from prior year
Company cut full-yr 2026 EBITDA guidance but raised revenue outlook amid price pressure and reimbursement limits

Outlook
Medios AG raises 2026 revenue guidance to €2.1 bln–€2.16 bln from €2.0 bln–€2.12 bln
Company lowers 2026 EBITDA pre guidance to €88 mln–€92 mln from €94 mln–€102 mln

Result Drivers
PRICE PRESSURE - Co cited continued price pressure in the Pharmaceutical Supply segment as a reason for lower earnings
CANNABIS REIMBURSEMENT - Restricted reimbursement eligibility in the medical cannabis business weighed on earnings, per co
INTERNATIONAL BUSINESS - Slightly weaker business in the International Business segment contributed to lower earnings

Company press release: ID:nEQ7GKK0Ka

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 ADJ-EBITDA
 
EUR 44 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Medios AG is €24.00, about 96.1% above its July 28 closing price of €12.24
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 10 three months ago

Reuters Recommended Reads
July 28 - Italy's Recordati H1 revenue rises 6.6% on rare diseases segment growth
July 28 - Jet engine maker Safran raises targets after record first-half margin
July 27 - Universal Health Services cuts 2026 forecast on Medicaid reimbursement uncertainty

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)